Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma
- Authors: Vorobyev VI1, Gemdzhian EG2, Dubrovin EI1, Nesterova ES2, Kaplanov KD3, Volodicheva EM4, Zherebtsova VA1, Kravchenko SK2
-
Affiliations:
- Botkin Moscow City Clinical Hospital
- National Research Center for Hematology
- Volgograd Regional Clinical Oncologic Dispensary
- Tula Region Hospital
- Issue: Vol 91, No 7 (2019)
- Pages: 41-51
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33594
- DOI: https://doi.org/10.26442/00403660.2019.07.000322
- ID: 33594
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
V I Vorobyev
Botkin Moscow City Clinical Hospital
Email: morela@mail.ru
к.м.н., врач-гематолог гематологического отд-ния №6 ГБУЗ «ГКБ им. С.П. Боткина» ДЗМ Moscow, Russia
E G Gemdzhian
National Research Center for Hematologyс.н.с. лаб. биостатистики «НМИЦ гематологии» Минздрава России; ORCID: 0000-0002-8357-977x Moscow, Russia
E I Dubrovin
Botkin Moscow City Clinical Hospitalврач-гематолог гематологического отд-ния №6 ГБУЗ «ГКБ им. С.П. Боткина» ДЗМ Moscow, Russia
E S Nesterova
National Research Center for Hematologyврач-гематолог отд-ния интенсивной высокодозной химиотерапии гемобластозов с круглосуточным и дневным стационаром «НМИЦ гематологии» Минздрава России Moscow, Russia
K D Kaplanov
Volgograd Regional Clinical Oncologic Dispensaryк.м.н., зав. отд-нием гематологии Волгоградского областного онкологического диспансера Volgograd, Russia
E M Volodicheva
Tula Region Hospitalзав. отд-нием гематологии Тульской областной клинической больницы Tula, Russia
V A Zherebtsova
Botkin Moscow City Clinical Hospitalк.м.н., врач-гематолог гематологического отд-ния №6 ГБУЗ «ГКБ им. С.П. Боткина» ДЗМ Moscow, Russia
S K Kravchenko
National Research Center for Hematologyк.м.н., доцент, зав. отд-нием интенсивной высокодозной химиотерапии гемобластозов с круглосуточным и дневным стационаром «НМИЦ гематологии» Минздрава России Moscow, Russia
References
- Swerdlow S, Campo E, Harris N.L, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th edn. Lyon: International Agency for Research on Cancer, 2017:285-291.
- Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113:791-8. doi: 10.1002/cncr.23608
- Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol. 2014;25(suppl 3):iii83-92. doi: 10.1093/annonc/mdu264
- Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984-92. doi: 10.1200/JCO.2005.08.133
- Hoster E, Unterhalt M, Pfreundschuh M, et al. The addition of rituximab to CHOP improves failure - free and overall survival of mantle - cell lymphoma patients - a pooled trials analysis of the German Low-Grade Lymphoma Study Group (GLSG). Blood. 2014;124:1752 (abstr).
- Howard O.M, Gribben J.G, Neuberg D.S, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression - free survival. J Clin Oncol. 2002;20:1288-94. doi: 10.1200/JCO.2002.20.5.1288
- Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression - free survival in mantle - cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677-84. doi: 10.1182/blood-2004-10-3883
- Witzens-Harig M., Ho A.D., Foá R., Di Rocco A., van Hazel G., Chamone D.F.A., Rowe J.M., Arcaini L., Poddubnaya I., Ivanova V., Vranovsky A., Thurley D., Oertel S. Annals of Hematology. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase III maxima study. 2014. Т. 93. № 10. С. 1717-1724.
- Geisler C.H, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six - year follow - up after intensive immunochemotherapy for untreated mantle celllymphoma followed by BEAM or BEAC + autologous stem - cell support: still very long survival but late relapses do occur. Br J Haematol. 2012 Aug;158(3):355-62. doi: 10.1111/j.1365-2141.2012.09174.x
- Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: first interim analysis of the phase III Prospective Lyma Trial, a Lysa Study. 56th American Society of Hematology Annual Meeting; San Francisco, CA; Dec 6-9, 2014:124.
- Hermine O, Hoster E, Walewski J, et al. Addition of high - dose cytarabine to immunochemotherapy before autologous stem cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open - label, phase 3 trial ofthe European Mantle Cell Lymphoma Network. Lancet. 2016 Aug 6;388(10044):565-75. doi: 10.1016/S0140-6736(16)00739-х
- Romaguera J.E, Fayad L, Rodriguez M.A, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle - cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high - dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013-23. doi: 10.1200/JCO.2005.01.1825
- Merli F, Luminari S, Ilariucci F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicenter trial from Gruppo Italiano Studio Linfoni. Br J Haematol. 2012;156(3):346-53. doi: 10.1111/j.1365-2141.2011.08958.x
- Bernstein S.H, Epner E, Unger J.M, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013;24:1587-93. doi: 10.1093/annonc/mdt070
- Rodriguez J, Gutierrez A, Palacios A, et al. Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma. 2007;48:2172-8. doi: 10.1080/10428190701618268
- Corazzelli G, Capobianco G, Arcamone M, et al. Long - term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant - ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol. 2009;64:907-16. doi: 10.1007/s00280-009-0941-9
- Corazzelli G, Russo F, Capobianco G, et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol. 2006;17(Suppl 4):iv18-24. doi: 10.1093/annonc/mdj994
- Park B.B, Kim W.S, Eom H.S, et al. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. Invest New Drugs. 2011;29:154-60. doi: 10.1007/s10637-009-9320-y
- Suzumiya J, Suzushima H, Maeda K, et al. Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma. Int J Hematol. 2004 Apr;79(3):266-70.
- Hara S, Yokote T, Akioka T, et al. Successful treatment of refractory mantle cell lymphoma with irinotecan. Rinsho Ketsueki. 2005 May;46(5):358-62.
- Воробьев В.И., Кравченко С.К., Гемджян Э.Г. и др. Мантийноклеточная лимфома: программное лечение первичных больных в возрасте до 65 лет. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2013;6(3):274-81.
- Vorobyev V.I, Kravchenko S.K, Gemdzhian E.G, et al. Less Toxic Gemcitabine-Oxaliplatin Based Induction Regimen (R-GIDIOX) Prior to Autologous SCT Produces Outcomes Similar to High-Dose Cytarabine Containing Intensive Induction Regimen in Mantle Cell Lymphoma - a Follow up Report of the Multicenter Study. Blood. 2014;124(21):1726.
- Воробьев В.И., Лорие Ю.Ю., Мангасарова Я.К. и др. Возможности терапии рецидивов и резистентного течения лимфомы из клеток мантийной зоны. Гематология и трансфузиология. 2011;(1):34-7.
- Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний под ред. И.В. Поддубной, В.Г. Савченко. М., 2018.
- Cheson B, Pfistner B, Juweid M, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86. doi: 10.1200/JCO.2006.09.2403
- Geisler C.H, Kolstad A, Laurell A, Long - term progression - free survival of mantle cell lymphoma after intensive front - line immunochemotherapy with in vivo - purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008 Oct 1;112(7):2687-93. doi: 10.1182/blood-2008-03-147025
- Chihara D, Cheah C.Y, Westin J.R, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantlecell lymphoma: 15-year follow - up of a phase II study from the MD Anderson Cancer Center. Br J Haemotol. 2016 Jan;172(1):80-8. doi: 10.1111/bjh.13796
- Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood. 2013;121: 48-53. doi: 10.1182/blood-2011-09-370320
- Eskelund C.W, Kolstad A, Jerkeman M, et al.15-year follow - up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016 Nov;175(3):410-8. doi: 10.1111/bjh.14241
- Robak T, Jin J, Pylypenko H, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation - ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open - label, phase 3 study. Lancet Oncol. 2018 Nov;19(11):1449-58. doi: 10.1016/S1470-2045(18)30685-5
- Geisler C. Front - line therapy of MCL. Hematologica. 2010;95:1241-3. doi: 10.3324/haematol.2010.025627
- Salles G, Seymour J.F, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7
- Chang J.E, Peterson C, Choi S, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011;155(2):190-7. doi: 10.1111/j.1365-2141.2011.08820.x
- Kenkre V.P, Long W.L, Eickhoff J.C, et al. Maintenance rituximab following induction chemoimmunotherapy for mantle cell lymphoma: long - term follow - up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011; 52(9):1675-80. doi: 10.3109/10428194.2011.580404
- Kluin-Nelemans H.C, Hoster E, Hermine O, et al. Treatment of older patients with mantle - cell lymphoma. N Engl J Med. 2012;367(6):520-31. doi: 10.1056/NEJMoa1200920
- Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med. 2017;377: 1250-60. doi: 10.1056/NEJMoa1701769
- Eskelund C.W, Dahl C, Hansen J.W, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017 Oct 26;130(17):1903-10. doi: 10.1182/blood-2017-04-779736
- Baker J, Giralt S, Hamlin P, Jakubowski A, Castro-Malaspina H, Robinson K.S, Papadopoulos E.B, Perales M, Sauter C. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol. 2019 Mar;184(6):1006-10. doi: 10.1111/bjh.15721
- Visco C, Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low - dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5
- Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle - cell lymphoma: an international, randomised, open - label, phase 3 study. Lancet. 2016;387:770-8. doi: 10.1016/S0140-6736(15)00667-4
- Trneny M, Lamy T, Walewski J, et al. Phase II randomized, multicenter study of lenalidomide vs best investigator’s choice in relapsed/refractory mantle cell lymphoma: results of the MCL-002 (SPRINT) study. 56th American Society of Hematology Annual Meeting; San Francisco, CA; Dec 6-9, 2014:124.
- Davids M.S, Roberts A.W, Seymour J.F. Phase I First - in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10;35(8):826-33. doi: 10.1200/JCO.2016.70.4320
- Toby A. Eyre, Harriet S. Walter, Sunil Iyengar. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018
- Martin P. The use of CAR T-cells in diffuse large B-cell lymphoma and mantle cell lymphoma. Clin Adv Hematol Oncol. 2017 Apr;15(4):247-9.
- Li T, Zhang Y, Peng D. A good response of refractory mantel cell lymphoma to haploidentical CAR T-cell therapy after failure of autologous CAR T-cell therapy. J Immunother Cancer. 2019 Feb 21;7(1):51. doi: 10.1186/s40425-019-0529-9
- Dreyling M, Aurer I, Cortelazzo S. Treatment for patients with relapsed/refractory mantle cell lymphoma: European - based recommendations. Leuk Lymphoma. 2018 Aug;59(8):1814-28. doi: 10.1080/10428194.2017.1403602
- Wang M, Rule S, Zinzani P.L, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single - arm, multicentre, phase 2 trial. Lancet. 2018 Feb 17;391(10121):659-67. doi: 10.1016/S0140-6736(17)33108-2
- Tam C.S, Anderson M.A, Pott C, et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med. 2018 Mar 29;378(13):1211-23. doi: 10.1056/NEJMoa1715519.
![](/img/style/loading.gif)